Till startsida
University of Gothenburg
Sitemap
To content Read more about how we use cookies on gu.se

Group Jonas Nilsson

Research summary

We try to identify new means to treat cancer based on our previous research on the oncogenic transcription factor c-Myc. This research has pointed on potential targets for anti-cancer drugs including kinases, epigenetic readers and metabolic enzymes.

Recently the group's activities has shifted into translating the knowledge gained from the Myc research into melanoma. Myc is overexpressed in melanoma so therefore its expression is not an optimal biomarker to define which of our previously identified targets would be viable in melanoma.

Our new research therefore seek to identify biomarkers of response to new targeted therapies. We are also making personalized animal models, so called PDX models or Avatar mice. These are used to test drugs as well as further humanization for use in immune oncology research.

The research has generated the framework of starting the Sahlgrenska Translational Melanoma Group (SATMEG), consisting of basic researchers and clinical investigators working together to devise new therapies against melanoma. Read more about SATMEG activities here:

Sahlgrenska Translational Melanoma Group (SATMEG)

Group members at SCC

Lead:
Jonas Nilsson, PhD, Group leader at Sahlgrenska Cancer Center and Professor of Experimental Cancer Surgery
Phone: +46 (0)31 786 6768
E-mail: jonas.a.nilsson@surgery.gu.se

Senior Research Fellows:
Lisa Nilsson, PhD, Senior staff scientist
Lars Ny, MD/PhD, Associate professor, oncologist
Berglind Einarsdottir, PhD, Postdoctoral fellow
Paul-Steffen Kuhn, PhD, Postdoctoral fellow
Larissa Rizzo, PhD, Postdoctoral fellow

Post-graduate students:
Henrik Jespersen, MD, Resident in Oncology, PhD student
Elin Söderberg, MSc, PhD student
Valerio Belgrano, MD, PhD student

Technical staff:
Sofia Stenqvist, animal technician

Affiliated members:
Sahlgrenska Translational Melanoma Group (SATMEG)

Selected publications

  1. HER2 CAR-T cells eradicate uveal melanoma and T cell therapy-resistant human melanoma in interleukin-2 (IL-2) transgenic NOD/SCID IL-2 receptor knockout mice.
    Forsberg EM, Lindberg MF, Jespersen H, Alsén S, Olofsson Bagge R, Donia M, Svane IM, Nilsson O, Ny L, Nilsson LM, Nilsson JA. Cancer Res. 2019
     
  2. Response and Toxicity of Repeated Isolated Limb Perfusion (re-ILP) for Patients With In-Transit Metastases of Malignant Melanoma.
    Belgrano V, Pettersson J, Nilsson JA, Mattsson J, Katsarelias D, Olofsson Bagge R. Ann Surg Oncol. 2019
     
  3. Mouse avatars take off as cancer models.
    Nilsson JA, Olofsson Bagge R, Ny L.
    Nature. 562(7726):192, 2018
     
  4. A patient-derived xenograft pre-clinical trial reveals treatment responses and a resistance mechanism to karonudib in metastatic melanoma.
    Einarsdottir BO, Karlsson J, Söderberg EMV, Lindberg MF, Funck-Brentano E, Jespersen H, Brynjolfsson SF, Bagge RO, Carstam L, Scobie M, Koolmeister T, Wallner O, Stierner U, Berglund UW, Ny L, Nilsson LM, Larsson E, Helleday T, Nilsson JA. Cell Death Dis. 9(8):810, 2018
     
  5. BET bromodomain inhibitors synergize with ATR inhibitors in melanoma. Muralidharan SV, Einarsdottir BO, Bhadury J, Lindberg MF, Wu J, Campeau E, Bagge RO, Stierner U, Ny L, Nilsson LM, Nilsson JA. Cell Death Dis. 8(8):e2982, 2017
     
  6. Clinical responses to adoptive T-cell transfer can be modeled in an autologous immune-humanized mouse model.
    Jespersen H, Lindberg MF, Donia M, Söderberg EMV, Andersen R, Keller U, Ny L, Svane IM, Nilsson LM, Nilsson JA. Nat Commun. 8(1):707, 2017
     
  7. An approach to suppress the evolution of resistance in BRAFV600E-mutant cancer.
    Xue Y, Martelotto L, Baslan T, Vides A, Solomon M, Mai TT, Chaudhary N, Riely GJ, Li BT, Scott K, Cechhi F, Stierner U, Chadalavada K, de Stanchina E, Schwartz S, Hembrough T, Nanjangud G, Berger MF, Nilsson J, Lowe SW, Reis-Filho JS, Rosen N, Lito P. Nat Med. 23(8):929-937, 2017
     
  8. BRAFV600 inhibition alters the microRNA cargo in the vesicular secretome of malignant melanoma cells.
    Lunavat TR, Cheng L, Einarsdottir BO, Olofsson Bagge R, Veppil Muralidharan S, Sharples RA, Lässer C, Gho YS, Hill AF, Nilsson JA, Lötvall J. Proc Natl Acad Sci U S A. 114(29):E5930-E5939, 2017
     
  9. Acquired Immune Resistance Follows Complete Tumor Regression without Loss of Target Antigens or IFNγ Signaling.
    Donia M, Harbst K, van Buuren M, Kvistborg P, Lindberg MF, Andersen R, Idorn M, Munir Ahmad S, Ellebæk E, Mueller A, Fagone P, Nicoletti F, Libra M, Lauss M, Hadrup SR, Schmidt H, Andersen MH, Thor Straten P, Nilsson JA, Schumacher TN, Seliger B, Jönsson G, Svane IM. Cancer Res. 77(17):4562-4566, 2017
     
  10. Validation and development of MTH1 inhibitors for treatment of cancer.
    Warpman Berglund U, Sanjiv K, Gad H, Kalderén C, Koolmeister T, Pham T, Gokturk C, Jafari R, Maddalo G, Seashore-Ludlow B, Chernobrovkin A, Manoilov A, Pateras IS, Rasti A, Jemth AS, Almlöf I, Loseva O, Visnes T, Einarsdottir BO, Gaugaz FZ, Saleh A, Platzack B, Wallner OA, Vallin KS, Henriksson M, Wakchaure P, Borhade S, Herr P, Kallberg Y, Baranczewski P, Homan EJ, Wiita E, Nagpal V, Meijer T, Schipper N, Rudd SG, Bräutigam L, Lindqvist A, Filppula A, Lee TC, Artursson P, Nilsson JA, Gorgoulis VG, Lehtiö J, Zubarev RA, Scobie M, Helleday T.
    Ann Oncol. 27(12):2275-2283, 2016

 

PubMed

 

Page Manager: Yael Zukovsky Fitoussi|Last update: 1/16/2019
Share:

The University of Gothenburg uses cookies to provide you with the best possible user experience. By continuing on this website, you approve of our use of cookies.  What are cookies?